1 July 2015 in International Journal of Cardiology
1 January 2013 in Cellular Physiology and Biochemistry
Background: SIRT5 is located in the mitochondria, and plays a crucial role in the regulation of metabolic process and cellular apoptosis. Cardiomyocytes are abundant in mitochondria. However, the role of SIRT5 in oxidative stress-induced apoptosis is still unknown in cardiomyocytes. Methods and Results: Western blots analysis revealed that SIRT5 is significantly down-regulated in cardiomyocytes upon oxidative stress. MTT assay, DAPI staining, and caspase 3/7 activity assay were used to estimate apoptosis development. The result suggested that compared with the wild-type group, SIRT5 knockdown results in a marked reduction in cell viability, and a significant increase in the number of apoptotic cells and the caspase 3/7 activity. Protein immunoprecipitation revealed a direct interaction between Bcl-Xl and SIRT5. Apoptosis assay and western blot anaylsis suggested that SIRT5 levels could affect the levels of Bcl-Xl expression, but have no effect on the apoptosis development in Bcl-Xl knockdown cells. Conclusion: This study reveals a novel role of SIRT5 in the regulation of oxidative stress-induced apoptosis in cardiomyocytes. Pharmacological interventions on SIRT5 expression may be useful in the treatment of oxidative stress-related cardiac injury.
4 July 2017 in Scientific Reports
Diabetes increases the risk of Cardio-vascular disease (CVD). CVD is more prevalent in type 2 diabetes (T2D) than type 1 diabetes (T1D), but the mortality risk is higher in T1D than in T2D. The pathophysiology of CVD in T1D is poorly defined. To learn more about biological pathways that are potentially involved in T1D with cardiac dysfunction, we sought to identify differentially expressed genes in the T1D heart. Our study used T1D mice with severe hyperglycemia along with significant deficits in echocardiographic measurements. Microarray analysis of heart tissue RNA revealed that the T1D mice differentially expressed 10 genes compared to control. Using Ingenuity Pathway Analysis (IPA), we showed that these genes were significantly involved in ketogenesis, cardiovascular disease, apoptosis and other toxicology functions. Of these 10 genes, the 3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 (HMGCS2) was the highest upregulated gene in T1D heart. IPA analysis showed that HMGCS2 was center to many biological networks and pathways. Our data also suggested that apart from heart, the expression of HMGCS2 was also different in kidney and spleen between control and STZ treated mice. In conclusion, The HMGCS2 molecule may potentially be involved in T1D induced cardiac dysfunction.
1 November 2015 in The American Journal of the Medical Sciences
5 April 2017 in Journal of the American Heart Association
Background: Translocase of inner membrane 50 ( TIM 50) is a member of the translocase of inner membrane ( TIM ) complex in the mitochondria. Previous research has demonstrated the role of TIM 50 in the regulation of oxidative stress and cardiac morphology. However, the role of TIM 50 in pathological cardiac hypertrophy remains unknown. Methods and Results: In the present study we found that the expression of TIM 50 was downregulated in hypertrophic hearts. Using genetic loss‐of‐function animal models, we demonstrated that TIM 50 deficiency increased heart and cardiomyocyte size with more severe cardiac fibrosis compared with wild‐type littermates. Moreover, we generated cardiomyocyte‐specific TIM 50 transgenic mice in which the hypertrophic and fibrotic phenotypes were all alleviated. Next, we tested reactive oxygen species generation and the activities of the antioxidant enzymes superoxide dismutase and catalase, and also respiratory chain complexes I, II, and IV, finding that all the activities were regulated by TIM 50. Meanwhile, expression of the ASK 1‐ JNK /P38 axis was increased in TIM 50‐deficient mice, and TIM 50 overexpression decreased the activity of the ASK 1‐ JNK /P38 axis. Finally, we treated mice with the antioxidant N‐acetyl cysteine to reduce oxidative stress. After N‐acetyl cysteine treatment, the deteriorative hypertrophic and fibrotic phenotypes caused by TIM 50 deficiency were all remarkably reversed. Conclusions: These data indicated that TIM 50 could attenuate pathological cardiac hypertrophy primarily by reducing oxidative stress. TIM 50 could be a promising target for the prevention and therapy of cardiac hypertrophy and heart failure.
14 August 2012 in Clinical Endocrinology